How to buy Enfusion stock (Enfusion)

Enfusion, which produces Cloud-based investment management software, wrapped its IPO, selling 15.322 million shares at $17 per share, the high end of its announced price range.

Shares of Enfusion will begin trading on the NYSE later today under the ticker symbol ENFN, but shares are available for limit orders on Robinhood and other platforms.

Our top picks for where to buy Enfusion stock

Buy Enfusion stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Enfusion stock price (NYSE: ENFN)

Use our graph to track the performance of ENFN stocks over time.

Enfusion shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$10.63
52-week range	$7.52 - $11.38
50-day moving average more info button	$9.58
200-day moving average more info button	$9.07
Wall St. target price	$9.61
PE ratio more info button	268.75
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$0.04

Is it a good time to buy Enfusion stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Enfusion price performance over time

Historical closes compared with the close of $10.63 from 2024-12-20

1 week (2024-12-13)	-0.19%
1 month (2024-11-22)	2.61%
3 months (2024-09-20)	18.37%
6 months (2024-06-21)	27.76%

1 year (2023-12-22)	9.81%
2 years (2022-12-22)	19.17%
3 years (2021-12-22)	18.71
5 years (2019-12-18)	N/A

Is Enfusion stock undervalued or overvalued?

Valuing Enfusion stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Enfusion's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Enfusion's P/E ratio

Enfusion's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 269x. In other words, Enfusion shares trade at around 269x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

However, Enfusion's P/E ratio is best considered in relation to those of others within the software - application industry or those of similar companies.

• X Financial Class A (XYF.US): 2.02
• Moneygram Int (MGI.US): 32.32
• PayPal (PYPL.US): 20.44

Enfusion's EBITDA

Enfusion's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $18.5 million.

The EBITDA is a measure of a Enfusion's overall financial performance and is widely used to measure a its profitability.

To put Enfusion's EBITDA into context you can compare it against that of similar companies.

• X Financial Class A (XYF.US): USD$1.6 billion
• Moneygram Int (MGI.US): USD$189.6 million
• PayPal (PYPL.US): USD$6.1 billion

Enfusion financials

Revenue TTM	$195.2 million
Operating margin TTM	5.83%
Gross profit TTM	$103.2 million
Return on assets TTM	5.92%
Return on equity TTM	5.48%
Profit margin	1.7%
Book value	$0.75
Market Capitalization more info button	$1 billion

TTM: trailing 12 months

Enfusion share dividends

We're not expecting Enfusion to pay a dividend over the next 12 months.

You may also wish to consider:

• X Financial Class A (XYF.US) (4.89% forward annual dividend yield)

Enfusion share price volatility

Over the last 12 months, Enfusion's shares have ranged in value from as little as $7.52 up to $11.375. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Enfusion's is 0.934. This would suggest that Enfusion's shares are less volatile than average (for this exchange).

To put Enfusion's beta into context you can compare it against those of similar companies.

• X Financial Class A (XYF.US): 0.316
• Moneygram Int (MGI.US): 0.9947
• PayPal (PYPL.US): 1.436

Enfusion overview

Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. It also offers Accounting/General Ledger System, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion Analytics System, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion, Inc. was founded in 1997 and is headquartered in Chicago, Illinois. .

Frequently asked questions

null
What percentage of Enfusion is owned by insiders or institutions?
Currently 5.524% of Enfusion shares are held by insiders and 96.831% by institutions. How many people work for Enfusion?
Latest data suggests 1,102 work at Enfusion. When does the fiscal year end for Enfusion?
Enfusion's fiscal year ends in December. Where is Enfusion based?
Enfusion's address is: 125 South Clark Street, Chicago, IL, United States, 60603 What is Enfusion's ISIN number?
Enfusion's international securities identification number is: US2928121043